4-methyl-2-mercaptophenol | 60774-07-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: 4-methyl-2-mercaptophenol
• 英文别名: 2-hydroxy-5-methylthiophenol；2-mercapto-4-methylphenol；4-methyl-2-sulfanylphenol；4-methyl-mercapto-phenol；4-Methyl mercaptophenol
• CAS: 60774-07-4
• 化学式: C₇H₈OS
• mdl: MFCD18451640
• 分子量: 140.206
• InChiKey: GWMWXFGQYATKBA-UHFFFAOYSA-N

物化性质

• 熔点：
  101-103 °C(Solv: acetic acid (64-19-7); water (7732-18-5))
• 沸点：
  117-118 °C(Press: 20 Torr)
• 密度：
  1.200±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  21.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methyl-2-mercaptophenol 在 吡啶 、 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 反应 54.0h， 生成 11-(Dicyanomethylene)-3-methylbenzonaphtho<2,3-e><1,4>oxathiin-6-one
  参考文献：
  名称：

  Single-Component Donor-Acceptor Organic Semiconductors Derived from TCNQ

  摘要：

  13,13,14,14-Tetracyanobenzo[b]naphtho[2,3-e][1,4]dithiin-6,11-quinodimethane (9a) and 13,13,14,14-tetracyanobenzo[b]naphtho[2,3-e] [1,4]oxathiin-6,11-quinodimethane (10a) and their methyl-substituted derivatives(9b and 10b-d, respectively) have been prepared as single-component donor-acceptor compounds from the corresponding quinones 7 and 8 by using the Lehnert's reagent. UV-vis spectra of the novel compounds reveal the presence of an intramolecular electronic transfer from the donor to the acceptor moiety. Cyclic voltammetry displays, in addition to the oxidation peak, a two-electron reduction wave to the dianion, as confirmed by controlled potential coulometry analysis. The crystallographical study carried out on single crystals of compound 10d shows that molecules are not planar and stack with aromatic interactions between donor and acceptor moieties. In agreement with the crystallographical results, the electrical conductivity measured on a powder sample of 10c exhibits semiconductive behavior. Molecular orbital calculations using the PM3 semiempirical method were performed on both neutral and oxidized/reduced compounds and predict that molecules are severely distorted from planarity. Distortions are compared with crystallographic data and are analyzed in terms of nonbonding interactions and crystal packing. Valence effective Hamiltonian (VEH) nonempirical calculations were used to study the electronic properties and support the intramolecular charge-transfer nature of the lowest-energy absorption band. The evolution of the geometric structure evidences a gain of aromaticity upon oxidation and reduction that just the obtention of stable cations and,anions. The observation of a unique two-electron reduction wave to the dianion is rationalize;by comparing the electronic and structural changes induced by reduction on compound 9a and on the parent TCNQ molecule.

  DOI：

  10.1021/jo00095a042
• 作为产物：
  描述：

  5-methylbenzo[d][1,3]oxathiol-2-one 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.25h， 以83%的产率得到4-methyl-2-mercaptophenol
  参考文献：
  名称：

  Regiocontrolled Carbonylsulfanylations at ortho-Position of Phenols and at α-Position of Ketones Using Chlorocarbonylsulfenyl Chloride

  摘要：

  DOI：

  10.3987/com-98-s(h)23

文献信息

• Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
  申请人：DEVELOPMENT CENTER FOR BIOTECHNOLOGY

  公开号：US20030229017A1

  公开（公告）日：2003-12-11

  A solid phase synthesis method for preparing peptide-spacer-lipid conjugates, the peptide-spacer-lipid conjugates synthesized by the method, and liposomes containing the peptide-spacer-lipid conjugates. The present invention provides a convenient solid phase synthesis method for preparing peptide-spacer-lipid conjugates and provides various linkage groups (such as amide group) for conjugating peptide, spacer and lipid, wherein the spacer may comprise PEG. Several advantages can be achieved, such as the synthetic procedure can be simplified, the synthesis process can be set to automation, the purification is easier in each reaction step, and the product losses can be reduced to minimal during synthesis. The present synthesis method is suitable for preparing a wide range of peptide-spacer-lipid conjugates, provides a peptide-spacer-lipid conjugate prepared by the solid phase synthesis method of the present invention, which can be incorporated into a liposome as the targeting moiety for liposomal drug delivery to specific cells, and provides a targeting liposome containing the present peptide-spacer-lipid conjugate.

  一种用于制备肽-间隔子-脂质共轭物的固相合成方法，所述方法合成的肽-间隔子-脂质共轭物，以及含有肽-间隔子-脂质共轭物的脂质体。本发明提供了一种便利的固相合成方法，用于制备肽-间隔子-脂质共轭物，并提供了各种连接基团（如酰胺基团）用于连接肽、间隔子和脂质，其中间隔子可以包括PEG。可以实现几项优点，例如合成过程可以简化，合成过程可以设定为自动化，每个反应步骤中的纯化更容易，并且在合成过程中产品损失可以降至最低。本合成方法适用于制备各种肽-间隔子-脂质共轭物，提供了一种由本发明的固相合成方法制备的肽-间隔子-脂质共轭物，可作为靶向单元被纳入脂质体，用于将脂质体药物传递到特定细胞，并提供了含有本肽-间隔子-脂质共轭物的靶向脂质体。
• Benzoaxathiepin derivatives and their use as medicines
  申请人：——

  公开号：US20040127552A1

  公开（公告）日：2004-07-01

  The invention concerns 3-arylthio-propyl-amino-3,4-dihydro-2H-1,5-aryloxathiepin derivatives of general formula (I), wherein: R1 and R2, identical or different, represent a hydrogen atom, a fluorine atom or a chlorine atom, a hydroxy group, an alkyl, cyclopropyl, alkoxy, cyclopropoxy radical or when they occupy adjacent positions, form with the carbon atoms bearing them a carbon-containing cycle or an oxygen-containing heterocycle with five non-aromatic rings; R3 represents an alkyl radical, a hydroxy group or a methoxy radical; R4 represents a hydrogen atom or a methyl radical; and R 5 ?and R6, identical or different represent a hydrogen atom, an alkyl, alkoxy, alkylthio, alkylamino radical, or the groups OR4 and R5 form with the carbons which bear them a non-aromatic heterocycle with five or six rings containing at least an oxygen atom; and their pharmaceutically acceptable additions salts. 1

  该发明涉及一般式(I)的3-芳基硫代丙基氨基-3,4-二氢-2H-1,5-芳氧硫杂环戊烷衍生物，其中：R1和R2，相同或不同，代表氢原子、氟原子或氯原子、羟基、烷基、环丙基、烷氧基、环丙氧基基团或当它们占据相邻位置时，与携带它们的碳原子形成含碳环或含氧杂环的非芳香环，R3代表烷基基团、羟基或甲氧基基团；R4代表氢原子或甲基基团；R5和R6，相同或不同，代表氢原子、烷基、烷氧基、烷硫基、烷基氨基基团，或基团OR4和R5与携带它们的碳形成含至少一个氧原子的五元或六元环的非芳香杂环；以及它们的药学上可接受的盐。
• METHOD FOR PRODUCING CYANOGEN-HALIDE, CYANATE ESTER COMPOUND AND METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION
  申请人：MITSUBISHI GAS CHEMICAL COMPANY, INC.

  公开号：US20150299110A1

  公开（公告）日：2015-10-22

  A method for efficiently producing a cyanogen halide with suppressed side effects, and a method for producing a high-purity cyanate ester compound at a high yield includes contacting a halogen molecule with an aqueous solution containing hydrogen cyanide and/or a metal cyanide, so that the hydrogen cyanide and/or the metal cyanide is allowed to react with the halogen molecule in the reaction solution to obtain the cyanogen halide, wherein more than 1 mole of the hydrogen cyanide or the metal cyanide is used based on 1 mole of the halogen molecule, and when an amount of substance of an unreacted hydrogen cyanide or an unreacted metal cyanide is defined as mole (A) and an amount of substance of the generated cyanogen halide is defined as mole (B), the reaction is terminated in a state in which (A):(A)+(B) is between 0.00009:1 and 0.2:1.

  一种用于高效生产抑制副作用的氰卤化物，以及以高收率生产高纯度氰酸酯化合物的方法包括将卤素分子与含有氢氰酸和/或金属氰化物的水溶液接触，使得氢氰酸和/或金属氰化物与卤素分子在反应溶液中发生反应以获得氰卤化物，其中基于1摩尔卤素分子使用超过1摩尔的氢氰酸或金属氰化物，当未反应的氢氰酸或未反应的金属氰化物的物质量定义为摩尔(A)，生成的氰卤化物的物质量定义为摩尔(B)，反应在(A)：(A)+(B)介于0.00009:1和0.2:1之间的状态中终止。
• [EN] ANTIVIRAL PHARMACEUTICAL PREPARATION FOR USE IN TREATMENT OF HEPATITIS C<br/>[FR] PRÉPARATION PHARMACEUTIQUE ANTIVIRALE POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：POLITECHNIKA WROCLAWSKA

  公开号：WO2016051289A1

  公开（公告）日：2016-04-07

  The object of the present invention are novel peptide derivatives of diaryl esters of 1 - aminoalkylphosphonic acids and their use as inhibitors of NS3/4A protease expressed by human HCV virus in prophylaxis and therapy of viral hepatitis type C (VHC). The use of inhibitors with irreversible mechanism of inhibition in the treatment of HCV creates the possibility of effective improvement of the therapy inter alia by reducing the time of drug administration and limiting dosing to one drug.

  本发明的对象是新型肽衍生物，为1-氨基烷基膦酸二芳基酯的衍生物，以及它们作为人HCV病毒表达的NS3/4A蛋白酶的抑制剂在预防和治疗C型病毒性肝炎（VHC）中的应用。在HCV治疗中使用具有不可逆抑制机制的抑制剂，可以有效改善治疗，包括减少药物给予时间和将剂量限制为一种药物。
• 1,5-Benzoxathiepin derivatives. I. Synthesis and reaction of 1,5-benzoxathiepin derivatives.
  作者：HIROSADA SUGIHARA、HIROSHI MABUCHI、YUTAKA KAWAMATSU

  DOI：10.1248/cpb.35.1919

  日期：——

  Methyl 3-oxo-3, 4-dihydro-2H-1, 5-benzoxathiepin-4-carboxylates (3a-f) were synthesized by regioselective Dieckmann reaction of methyl 2-methoxycarbonylmethylthiophenoxyacetates (2a-f) [readily prepared from 2-mercaptophenols (la-f)] in fairly good yields. Alkylation of thc ketoester (3b) with alkyl halides gave 4-alkylated derivatives (7 and 8). A substituent at the 2-position on the 1, 5-benzoxathiepin ring was introduced by Dieckmann reaction of methyl ssubstituted 2-methoxycarbonylmethylthiophenoxyacetates (11, 12b and 12f). Thorpe-Ziegler reaction of 2-cyanomethylthiophenoxyacetonitriles (18a-d) gave 3-amino-2H-1, 5-benzoxathiepin-4-carbonitriles (19a-d). Novel heterocycles, 4-amino-11H-pyrimido [4, 5-c] [1, 5] benzoxathiepin derivatives (24-32), were synthesized by the reaction of enaminonitriles (3a and 3b) with amidines or guanidines.

  甲基3-氧基-3, 4-二氢-2H-1, 5-苯并噻噁烯-4-羧酸酯（3a-f）通过区域选择性的Dieckmann反应合成，起始物为甲基2-甲氧基羧基甲基噻吩氧乙酸酯（2a-f，易于由2-巯基苯酚（1a-f）制备而成），产率相当不错。对酮酸酯（3b）进行烷基化反应，使用烷基卤化物得到了4-烷基化衍生物（7和8）。通过对甲基取代的2-甲氧基羧基甲基噻吩氧乙酸酯（11, 12b和12f）进行Dieckmann反应，实现了在1, 5-苯并噻噁烯环的2位引入取代基。对2-氰甲基噻吩氧乙腈（18a-d）进行Thorpe-Ziegler反应，得到3-胺基-2H-1, 5-苯并噻噁烯-4-氰基（19a-d）。通过酰胺腈（3a和3b）与酰胺或胍反应，合成了新型杂环化合物4-氨基-11H-吡咯并[4, 5-c][1, 5]苯并噻噁烯衍生物（24-32）。